Pharma stocks showed resilience on July 9, with several companies like Laurus Labs and Lupin rising up to 3%. US President Donald Trump has reiterated that he would impose very high tariffs on ...

Pharma in Focus: Trump offers 18-month relief on pharma tariffs; Pharma stocks rise, Lupin, Biocon lead gains US President hints at steep pharmaceutical tariffs but offers 12–18 months of relief; ...

Aurobindo Pharma shares tumbled over 3 percent to trade at Rs 1,147 apiece in the morning, while Lupin shares dropped nearly 3 percent to trade at Rs 1,925 apiece.

Stock analysts noted that Indian companies like Zydus, Dr Reddy’s Labs, Lupin, Aurobindo, and Sun Pharma are heavily reliant on the US market – with US sales contributing 30-50 per cent of ...

The move is part of Lupin's broader strategy to create a specialised consumer healthcare entity, particularly aimed at capitalising on India's burgeoning self-care market.

Trump's threat of 200% tariff on pharmaceutical products could have severe implications on Indian drugmakers, as exports to the US form a significant share of their overall sales.

Lawmakers bet millions on pharma stocks as Trump targets industry Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

The study demonstrates promising results of prolonged release and a favorable safety profile of CBD following a single subcutaneous administration of LPT-CBD in minipigs.

Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment o ...

Louisiana accused pharmaceutical giant CVS of using its dominant market position to abuse customer information, drive up drug costs and unfairly undermine independent pharmacies.

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...